BioLineRx Ltd. Files 6-K Report
Ticker: BLRX · Form: 6-K · Filed: May 17, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, sec-report
TL;DR
BioLineRx filed a 6-K, attaching a press release. Check it for updates.
AI Summary
BioLineRx Ltd. filed a Form 6-K on May 17, 2024, to report a press release issued on the same date. The filing incorporates this press release into its effective registration statements under the Securities Act of 1933. The company is a foreign private issuer based in Israel.
Why It Matters
This filing indicates BioLineRx Ltd. is making new information publicly available, which could be material for investors to consider regarding the company's status and ongoing operations.
Risk Assessment
Risk Level: low — This is a routine filing to report a press release, not indicating any immediate operational or financial distress.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- May 17, 2024 (date) — Filing and press release date
- 001-35223 (other) — Commission file number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report a press release issued by BioLineRx Ltd. on May 17, 2024, and to incorporate it into the company's effective registration statements.
When was the press release filed with the SEC?
The press release was filed with the SEC on May 17, 2024, as part of the Form 6-K report.
What is BioLineRx Ltd.'s commission file number?
BioLineRx Ltd.'s commission file number is 001-35223.
Is BioLineRx Ltd. required to file annual reports under Form 20-F or Form 40-F?
Yes, BioLineRx Ltd. is required to file annual reports under Form 20-F.
Where is BioLineRx Ltd.'s principal executive office located?
BioLineRx Ltd.'s principal executive office is located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Filing Stats: 178 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-05-17 17:07:36
Filing Documents
- zk2431472.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 12KB
- image00001.jpg (GRAPHIC) — 402KB
- 0001178913-24-001769.txt ( ) — 575KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On May 17, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. This Form 6-K, including the exhibit attached hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: May 17, 2024